L eft atrial (LA) compliance 1 and contractility 2 are important determinants of left ventricular (LV) stroke volume. During LV isovolumetric contraction and systole, the compliant LA acts as a reservoir for pulmonary venous return and influences early LV diastolic filling pressure. On mitral valve opening, LA conduit and booster pump (contractile) functions enable passive and active LV filling, respectively. In the setting of LV diastolic dysfunction, the ability to augment LA reservoir capacity and booster pump function becomes critical for preserving LV filling and cardiac output. 3
LA Remodeling in Experimental HFpEF
signaling as seminal mechanisms. These are inherently not chamber-specific.
On the basis of this discord, we proposed a hypothesis that maladaptive alterations in LA structure and function could, in fact, be identified at an early stage of HFpEF development and would impair overall cardiac performance. To test this hypothesis, LA and LV properties and left atrioventricular coupling were defined using echocardiography, cardiac magnetic resonance imaging (MRI), and invasive pressure-volume loop analyses in a canine model of earlystage hypertensive HFpEF induced by aging, renal wrapinduced hypertension, and proinflammatory aldosterone excess. Chamber-specific fibrosis, myocyte hypertrophy, titin phosphorylation, and microvascular structure and endothelial function were assessed to elucidate pathophysiological mechanisms.
Methods

Animal Model
Nine elderly dogs (8-13 years; 25.5 [19.5-27.6 ] kg; 2 males; 7 females) underwent bilateral renal wrapping, which is an established model of experimental hypertension 12 (Methods I in the Data Supplement). Five weeks after surgery, intramuscular desoxycorticosterone pivalate (1.4 mg/kg) was administered to accentuate inflammation and model transition to HFpEF. 13, 14 Young control dogs (n=13; age ≈1 year; 23.9 [22.5-25.3] kg; 7 males; 6 females) underwent sham surgery alone. On judicious review of published data, young and elderly dogs without hypertension exhibit comparable LV dimensions, indexed mass, and fibrosis. 15 On the basis of the restricted availability of aged dogs, young dogs were, therefore, selected to undergo sham surgery, acknowledging the potential limitation. All animals were maintained in accordance with National Institutes of Health guidelines for the Care and Use of Laboratory Animals. 16 The study protocol was approved by the Mayo Clinic Institutional Animal Care and Use Committee.
Noninvasive Imaging
All dogs underwent 2D transthoracic echocardiography (Philips, 3.5 MHz transducer) in the conscious (standing) state before surgery and after 8 weeks (Methods II in the Data Supplement).
MRI (1.5-T scanner; GE Healthcare) was used to measure LA and LV chamber volumes and function at week 8 (Methods III in the Data Supplement). LA volume-time curves were constructed to determine LA maximum, minimum, mid-diastolic (end of rapid emptying), and preatrial contraction volumes. 17 LA reservoir, stroke, and conduit volumes, and LA function parameters were calculated according to standard equations ( Table I in 
In Vivo Hemodynamic Study
Open chest, open pericardium hemodynamic studies were performed at week 8 under anesthesia (IV propofol; 2-6 mg/kg, followed by inhaled isoflurane, 0.5%-2.5%). Mid-ascending aortic pressure and LV and LA pressure-volume loops were measured using 7F manometer-tipped pressure and 7F (LV) or 5F (LA) ADVantage admittance catheters (Scisense, Ontario, Canada). Hydraulic occluders were placed around the superior and inferior vena cava to allow acute preload reduction. Intravenous dextran was administered before hemodynamic measurements to achieve a LV end-diastolic pressure ≈20 mm Hg. All data were acquired with ventilation suspended at end-expiration and atrial pacing at 10 to 15 bpm above the sinus rate (Methods IV in the Data Supplement).
Pressure-Volume Analysis
LA end-systolic volume (LAV ES ) was taken as the minimum LA volume at end-atrial contraction. Its corresponding pressure defined LA end-systolic pressure (LAP ES ). LA end-reservoir volume (LAV ER ) and pressure (LAP ER ) were taken as the maximum LA volume and pressure immediately before mitral valve opening.
LA myocardial contractility was evaluated using a time-varying elastance model. 18, 19 LAP ES and LAV ES data from variably loaded pressure-volume loops were fit to the linear regression equation: LAP ES =E LA (LAV ES −V 0s ), where the slope of the end-systolic pressure-volume relation represents LA systolic elastance (E LA ) and V 0s is the extrapolated volume intercept of the relation. The coefficient of determination, R 2 , was used to describe goodness-of-fit for pressurevolume data to the linear model. Curvilinearity over the measured range of LA pressure and volumes yielded lower R 2 values.
LA compliance was assessed from LA end-reservoir data during vena cava occlusion. LAP ER and LAV ER were fit to the monoexponential equation LAP ER =αe β×LAV ER , where α reflects the y intercept (curve-fitting constant), e is the base of the natural logarithm, and β represents the dynamic stiffness constant (modulus of chamber stiffness). Data goodness-of-fit were assessed using R 2 . LV pressurevolume loops were analyzed as previously described (Methods IV in the Data Supplement). 20 At the end of the study, full-thickness LV and LA myocardial biopsies were obtained from the beating heart and flash-frozen in liquid nitrogen. Dogs were euthanized with intravenous potassium chloride under deep anesthesia, consistent with guidelines of the Panel on Euthanasia of the American Veterinary Medical Association. Harvested myocardial tissue was flash-frozen in liquid nitrogen and stored at −80°C. Additional sections were immediately fixed in 10% formalin solution and embedded in paraffin.
Fibrosis Assessment
Transmural 4-μm thick cross sections of LA and LV tissue were stained with picrosirius red to demonstrate extracellular matrix (Methods V in the Data Supplement) and scanned by whole-field digital microscopy. Interstitial fibrosis was expressed histomorphometrically as a percentage of total tissue area, excluding endocardial, epicardial, and perivascular regions (ImageJ, National Institutes of Health, Bethesda, MD) in the LA anterior free wall (LAFW), LA appendage (LAA), and LA posterior wall adjacent to the pulmonary veins (LAPW). Myocardial collagen content was determined using the hydroxyproline assay (Methods V in the Data Supplement).
Immunostaining and Fluorescence Microscopy
Cardiomyocyte cross-sectional area was determined by manual planimetry (ImageJ, National Institutes of Health) from 4-μm thick sections of paraffin-embedded LA and LV myocardial tissue stained with fluorescein isothiocyanate-conjugated wheat germ agglutinin (Vector Laboratories, Burlingame, CA), to delineate cell membranes (Methods VI in the Data Supplement). Minimum dimension was calculated as perpendicular to the delineated contour of the cell. A minimum of 100 cardiomyocytes were measured per section.
Titin Isoform Expression and Phosphorylation Status
Titin isoform expression was determined by SDS-PAGE and densitometry. Total phosphoprotein staining (Pro-Q Diamond) was used to assess total titin phosphorylation (Methods VII in the Data Supplement).
In Vitro Microvascular Function
LA microvessels were isolated from freshly harvested tissue and subjected to physiological levels of shear stress, as described previously, 21 in the presence or absence of intact endothelium, the endothelial nitric oxide synthase inhibitor N(ω)-nitro-L-arginine methyl ester (L-NAME), and iberiotoxin, an inhibitor of large conductance LA Remodeling in Experimental HFpEF Ca 2+ -activated K + (BK) channels involved in nitric oxide-mediated shear stress-induced vasodilation (SSD; Methods VIII in the Data Supplement).
Microvascular Density
Paraffin-embedded myocardial sections were stained with the biotinylated endothelial cell-specific marker isolectin B4 (Vector Laboratories, Burlington, VT). Microvascular density was quantified on whole-field digital micrographs using an automated color-detection algorithm (Definiens Tissue Studio 3.5; Definiens, Germany; Methods IX in the Data Supplement). Microvessels (small precapillary arterioles) were defined by a cross-sectional area of 78.5 to 314 μm 2 and average luminal diameter of 10 to 20 μm.
Statistics
Continuous variables are presented as median (25th-75th percentile). On the basis of the sample size, the Wilcoxon rank-sum (nonparametric) test was used to compare characteristics between HFpEF and control dogs. The Wilcoxon signed-rank test was used for withingroup comparisons of echocardiographic data at baseline (prior to surgery) versus week 8. Linear correlations between 2 variables were assessed using the Pearson correlation coefficient, r. Goodness of fit/ variance for pressure-volume data to regression models was assessed by the coefficient of determination, R 2 . P<0.05 (2-sided) was considered statistically significant. Analyses were performed using JMP, version 9.0 (SAS Institute Inc, Cary, NC).
Results
Model Development
Weekly postoperative blood pressures were higher in HFpEF dogs than controls ( Figure 1 ). Compared with baseline echocardiography (prior to surgery), HFpEF dogs at week 8 maintained a normal ejection fraction (≥50%); however, relative wall thickness and indexed LV mass increased and the LV diastolic dimension was diminished, indicating the development of concentric LV hypertrophy ( Table II in 
Left Ventricular Structure and Function
Cardiac MRI (at week 8) revealed greater LV mass and LV mass to end-diastolic volume ratio in HFpEF compared with controls, whereas ejection fraction and cardiac output were similar between groups ( Table 1 ). In vivo hemodynamic assessment revealed higher LV systolic elastance (Ees) and LV diastolic elastance (β LV ) in HFpEF versus controls and a trend toward higher arterial elastance (P=0.057) (Results I in the Data Supplement, Table III in the Data Supplement).
LA Geometry and Phasic Function
By MRI, at equivalent heart rate, LA volumes were greater in HFpEF than controls (Figure 2A and 2B) and positively correlated with the LV mass to end-diastolic volume ratio (r=0.62 to 0.70; P<0.01 for all). LA reservoir volume was similar between HFpEF and controls ( Table 1 ). LA stroke volume was significantly greater in HFpEF, whereas LA passive emptying volume was numerically, but not significantly, lower in HFpEF than controls. Accordingly, total LA emptying fraction was similar between groups because of increased LA active but reduced passive emptying fractions in HFpEF (Table 1 ). In both groups, LA conduit volume contributed the most to LV filling. Estimated LA kinetic energy expenditure 22 and heart rate-corrected mean LA ejection rate 23 were higher in HFpEF, suggesting greater LA stroke work and inotropy (Table 1 ). These findings indicate augmented LA active (booster pump) function in early-stage HFpEF without a concomitant increase in LA reservoir function.
LA Booster Pump Function and Systolic Atrioventricular Coupling
Representative LA pressure-volume loops are shown in Figures 3A and 3B . LA pressure-volume data during vena cava occlusion demonstrated a linear LA end systolic pressurevolume relationship (R 2 =0.96-0.99; Figure 3C ). At matched heart rate and mean LA pressure, the LA end systolic pressure-volume relationship slope (E LA ) was steeper and the volume axis intercept (V 0 ) was greater in HFpEF dogs compared with controls ( Figure 3D ; Table 2 ). When normalized for preload (ie, LAV ER ), E LA remained significantly greater in HFpEF, confirming increased LA systolic elastance ( Table 2 ). E LA was positively correlated with both LV systolic (Ees) and arterial (Ea) elastances ( Figure 3E ). LV Ees and Ea were also correlated (r=0.6; P=0.038) consistent with in-series left-sided coupling. The ratio of LV to LA systolic elastances, Ees/E LA was 0.66 (0.41-1.01) in control dogs, indicating greater LA than LV systolic elastance in the normal state ( Table 2 ). In HFpEF, the Ees/E LA ratio was higher (1.34 [0.99-1.63]; P=0.0069), indicating that atrial systolic stiffening does not match LV systolic stiffening in early-stage HFpEF. Impaired systolic atrioventricular coupling (higher Ees/E LA ) was associated with lower LV stroke volume ( Figure 3F ).
LA Compliance and Atrioventricular Coupling
End-reservoir LA pressure-volume data displayed a curvilinear relationship over the measured range ( Figure 3C ). Compared with controls, the LA end reservoir pressure-volume relationship was shifted leftward and upward in HFpEF (Figure 3D) , that is, the LA chamber stiffness constant (β LA ) was greater ( Table 2) , consistent with reduced LA compliance. Furthermore, β LA was inversely correlated with LV stroke volume (r=−0.46; P=0.04), suggesting that increased LA stiffness limits LV performance in HFpEF. Notably, β LA was not significantly correlated with maximum (P=0.24), preatrial contraction (P=0.10), or minimum (P=0.09) LA volume by MRI.
As the LA faces LV diastolic stiffness during atrial contraction, physiological left atrioventricular coupling may be Table 2) . A higher β LV /E LA ratio was significantly associated with lower LV stroke volume ( Figure 3F ).
LA and Ventricular Hypertrophy and Fibrosis
Autopsy LV mass index was numerically greater but not significantly different in HFpEF dogs compared with controls ( Figure 4A ). However, the ratio of LV mass (autopsy) to LV end-diastolic volume (MRI; Figure 4B ) and LV cardiomyocyte cross-sectional area ( Figure 4C and 4D) were significantly increased, indicating concentric LV hypertrophy.
Autopsy LA mass index ( Figure 4A ) and LA cardiomyocyte cross-sectional area ( Figure 4C and 4D) were greater in HFpEF dogs compared with controls. The ratio of LA mass (autopsy) to LAV ER (MRI; Figure 4B ) was conserved between groups, indicating eccentric LA hypertrophy. In the LAFW, LA appendage, and LV, there were no significant differences in interstitial fibrosis or collagen content, between HFpEF and controls ( Figure 5A-5C ). However, greater regional fibrosis was evident in the LA posterior wall of HFpEF dogs versus controls ( Figure 5A and 5C ). LA fibrosis exceeded LV fibrosis in all LA regions assessed. There was no correlation between LA or LV percentage fibrosis and LA or LV chamber stiffness constants (P>0.35 for all).
Titin Isoform Expression and Phosphorylation Status
Titin isoform expression was similar between groups in the LAFW, LA appendage, and LV ( Figure 6A and 6B ). In the LAFW, both N2B (stiffer) and N2BA (compliant) titin isoforms were hyperphosphorylated in HFpEF versus controls (Figure 6C ) and the extent of phosphorylation correlated with LA chamber stiffness (β LA versus N2B %phosphorylation, r=0.54, P=0.03; β LA versus N2BA %phosphorylation, r=0.49, P=0.05). Conversely, in the LA appendage, isoform N2B was hypophosphorylated in HFpEF and N2BA similar between groups (Figure 6C) . Neither status correlated with LA chamber stiffness.
In the LV, both N2B and N2BA titin isoforms were hyperphosphorylated in HFpEF versus controls ( Figure 6C ) and the degree of phosphorylation correlated with LV chamber stiffness (β LV versus N2B %phosphorylation, r=0.48, P=0.04; β LV versus N2BA %phosphorylation, r=0.52, P=0.03).
LA Microvessel Endothelial Function
Physiological shear stress produced graded dilatation of LA microvessels from both groups; however, SSD was significantly attenuated in microvessels from HFpEF dogs compared with controls ( Figure 7A ), suggesting reduced shear stress-mediated vasodilator generation in HFpEF. Removal of the endothelium markedly attenuated SSD in both groups ( Figure 7A ). Inhibition of endothelial nitric oxide synthase with L-NAME virtually abolished SSD in control dogs but only partially inhibited the vasodilator response in HFpEF vessels ( Figure 7B ), indicating impaired NO signaling in HFpEF. Blockade of BK channels with iberiotoxin, almost completely abolished SSD in control vessels but had only a marginal effect in microvessels from HFpEF dogs (Figure 7C ), suggesting that SSD in HFpEF microvessels is not BK channel dependent.
Microvessel Density
LA microvessel density was lower in HFpEF dogs than controls (2294 [1590-2712] vessels/mm 2 HFpEF versus 2694 [2245-2919] vessels/mm 2 controls; P=0.068) and inversely correlated with the LA chamber stiffness constant, β LA (Figure 7D ). LV microvessel density was also lower in HFpEF than controls (2678 [2485-2957] vessels/mm 2 HFpEF versus 3220 [3027-3399] vessels/mm 2 controls; P=0.0094) but did not significantly correlate with the LV chamber stiffness constant, β LV .
Discussion
The objective of this study was to determine whether maladaptive LA structural and functional remodeling was present in a canine model reflecting early-stage HFpEF comprising 
Presence of an Atrial Myopathy and Impaired Left Atrioventricular Coupling in Early-Stage HFpEF
LA enlargement is common in HFpEF and correlates with the severity and duration of LV diastolic dysfunction. 24 Accordingly, LA remodeling in HFpEF has been considered a late and adaptive response to increased LA afterload, 6,9 facilitating greater LA preload and augmented LA active emptying fraction, as per an atrial Frank-Starling mechanism. 25 In overt HFpEF, 6 as in some dilated 10 and hypertrophic 26 cardiomyopathies, this compensatory LA contractile response is blunted. In the present study of early-stage HFpEF, however, we did not find evidence of LA contractile failure. Rather, LA hypertrophy was accompanied by augmented booster pump function and inotropy relative to controls, including when normalized for LA volume. Even so, the enhanced LA inotropy was insufficient to match increases in LV endsystolic elastance or adequately compensate for increased LV diastolic stiffness in HFpEF, thereby giving rise to impaired systolic (higher Ees/E LA ) and physiological (higher β LV /E LA ) atrioventricular coupling. That both parameters of atrioventricular coupling inversely correlated with LV stroke volume suggest a key role for efficient mechanical matching between the LA and the LV in early-stage HFpEF. Similar abnormal atrioventricular coupling has been observed in patients with a recent myocardial infarction and in patients with HF and reduced ejection fraction 27 ; this study represents the first invasive assessment in HFpEF. Recent human HFpEF studies have also reported a reduction in LA compliance elicited on strain echocardiography 7, 9 or, in a single study, from steady-state LA pressure-volume co-ordinates (maximal v wave height minus a wave nadir divided by echocardiography-derived LA reservoir volume). 28 Herein, we provide verification of an upward and leftward shift in the LA end reservoir pressure-volume relationship, elicited during preload reduction in experimental HFpEF (ie, greater chamber stiffness or reduced compliance) versus controls, which negatively affected overall cardiac performance. This finding contrasts previous reports of LA adaptation in mild diastolic dysfunction, 3 essential hypertension without HF, 29 and LA volume overload in chronic mitral regurgitation, 30 where LA compliance and reservoir function increase to preserve LV filling and buffer elevated LA pressures.
Potential mechanisms for LA stiffening in HFpEF include greater fibrosis, increased cardiomyocyte stiffness (principally related to the sarcomeric protein titin), or LA myocardial ischemia. We did not observe an increase in LAFW or LV fibrosis in this model, consistent with other reports of LA fibrosis as a late finding. 31, 32 The observed increase in localized peripulmonary vein (LA posterior wall) fibrosis may signify the onset of a fibrotic response and substrate for AF genesis, which is frequent in HFpEF. 33 Similarly, LA and LV titin isoform composition were similar between HFpEF and controls; however, LA and LV total titin phosphorylation was increased in HFpEF, and N2B phosphorylation (the shorter stiffer isoform) modestly correlated with LA and LV chamber stiffness coefficients. Although site-specific titin phosphorylation and passive cardiomyocyte tension were not directly assessed, protein kinase Cα-mediated hyperphosphorylation of the titin proline, glutamate, valine, and lysine site is recognized to increase passive cardiomyocyte stiffness [34] [35] [36] and is a possible mechanism for this finding. Our corroborative demonstration of impaired NO signaling in HFpEF renders titin hyperphosphorylation less likely to result from cGMP-mediated mechanisms. Because LA and LV myocardium exhibited the same pattern, a chamberspecific response is also excluded and supports a process of global (all-chamber) adverse myocardial remodeling in HFpEF.
Lastly, attenuation of microcirculatory reserve has been associated with reduced LA compliance in experimental HF and reduced ejection fraction. 37 LA microvascular dysfunction, with impaired NO signaling, and microvascular rarefaction, as seen in this study, may contribute to LA diastolic dysfunction in early-stage HFpEF. Importantly, the inverse correlation between LA microvessel density and LA chamber stiffness, which was not observed in the LV, suggests that the LA is both vulnerable and potentially more sensitive than the LV to the effects of microvascular ischemia.
Inflammation and Endothelial Dysfunction in Early-Stage HFpEF
It is hypothesized that comorbidity-driven systemic and coronary microvascular inflammation results in impaired NO-cGMP signaling as the impetus to myocardial fibrosis and cardiomyocyte stiffening in HFpEF. 11 Our experimental model incorporates renal wrap-induced perinephritis and tubulointerstitial inflammation, 38 along with mineralocorticoid excess, which is proinflammatory in cardiac tissue. 13 In this setting, we demonstrated impaired endothelium-dependent LA microvascular vasodilator capacity. Because L-NAME did not completely block SSD in HFpEF dogs, we cannot rule out concomitant upregulation of an alternative endotheliumderived vasodilating factor, and therefore, further studies are required to elucidate the precise mechanism of SSD in HFpEF, to include age-matched controls. The additional presence of microvascular rarefaction, however, supports a role for microvascular inflammation in the development of HFpEF.
Limitations
Our experimental model incorporates well-established features of human HFpEF, including advanced age, hypertension, and proinflammatory mineralocorticoid excess; thus, our findings are relevant for a hypertensive HFpEF phenotype. Additional studies are required to evaluate LA parameters in HFpEF subjects without LV concentric remodeling. We recognize the limitation of not studying an elderly control group; however, our previous examination of this model exhibited similar characteristics between young and elderly control dogs with respect to LV and vascular remodeling and diastolic function, and distinct from dogs with experimental HF. 15 Thus, we believe our findings represent a significant effect of experimental HF, over and above that of aging alone. Importantly, elderly dogs available for research are frequently retired breeders, and therefore our sample is predominantly female. Published data demonstrate that sex differences in LA size are almost completely accounted for by body size 39 ; however, further examination of sex differences in LA function is warranted.
Conclusions
In the setting of hypertensive HFpEF, LA remodeling occurs early and exhibits maladaptive alterations in LA compliance and left atrioventricular coupling, which compromise overall cardiac performance and may exacerbate increases in LA and pulmonary pressures. 40, 41 Early development of LA noncompliance and atrioventricular mismatch may underlie reported associations between LA dysfunction and future HF in populations with preserved LV ejection fraction. 4, 5 Pathophysiological mechanisms, including myocardial hypertrophy, titin hyperphosphorylation, and microvascular rarefaction, affect LA and LV myocardium concomitantly, even in the absence of prolonged atrial hypertension or marked fibrosis, thus supporting a paradigm of global (all-chamber) adverse myocardial remodeling in HFpEF. Novel therapeutic strategies targeting these mechanisms may be able to lessen or reverse LA and LV remodeling in HFpEF and warrant investigation in human studies.
